Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Sells $249,998.00 in Stock

Key Points

• Alphatec COO Scott Lish sold 17,857 shares of the company stock for a total of $249,998, reducing his ownership by 2.52%.
• The company's stock recently reached a 52-week high of $15.34 with a significant trading volume of 5,877,914 shares.
• Alphatec reported a quarterly revenue of $185.54 million, surpassing analyst expectations, and projected -1.08 earnings per share for the year.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 17,857 shares of the business's stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $14.00, for a total transaction of $249,998.00. Following the transaction, the chief operating officer directly owned 690,998 shares of the company's stock, valued at $9,673,972. The trade was a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Scott Lish also recently made the following trade(s):

• On Tuesday, August 5th, Scott Lish sold 16,666 shares of Alphatec stock. The shares were sold at an average price of $15.00, for a total transaction of $249,990.00.
• On Friday, August 1st, Scott Lish sold 36,081 shares of Alphatec stock. The stock was sold at an average price of $12.53, for a total value of $452,094.93.
• On Thursday, July 10th, Scott Lish sold 3,982 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total value of $47,784.00.
• On Friday, June 13th, Scott Lish sold 22,727 shares of Alphatec stock. The shares were sold at an average price of $11.07, for a total transaction of $251,587.89.
• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The shares were sold at an average price of $13.00, for a total value of $719,875.00.

Alphatec Price Performance

Shares of Alphatec stock traded up $0.07 during midday trading on Friday, reaching $14.97. The company had a trading volume of 1,745,343 shares, compared to its average volume of 2,816,030. The stock has a fifty day simple moving average of $11.63 and a 200 day simple moving average of $11.28. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of -13.25 and a beta of 1.05. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $15.46.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.08. The firm had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The company's revenue was up 27.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.29) earnings per share. As a group, equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

ATEC has been the subject of a number of research analyst reports. Wall Street Zen upgraded Alphatec from a "hold" rating to a "buy" rating in a report on Saturday. Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 target price on the stock in a report on Monday, June 16th. Needham & Company LLC restated a "buy" rating and set a $16.00 price target on shares of Alphatec in a report on Friday, May 2nd. Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Friday, August 1st. Finally, Piper Sandler reiterated an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Alphatec presently has an average rating of "Buy" and a consensus target price of $18.50.

Hedge Funds Weigh In On Alphatec

Institutional investors have recently added to or reduced their stakes in the company. Comerica Bank boosted its holdings in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares during the period. Quarry LP boosted its stake in shares of Alphatec by 79.2% in the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after buying an additional 2,375 shares during the period. Larson Financial Group LLC acquired a new stake in Alphatec during the first quarter worth approximately $54,000. Nisa Investment Advisors LLC increased its stake in Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock worth $63,000 after acquiring an additional 1,045 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in Alphatec in the 4th quarter valued at $76,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.